Cancer Genetics — Merger or Acquisition (September 2020)
22 slides from Cancer Genetics's merger presentation, Sep 15, 2020
Slide 1: Cancer Genetics: De-risking and Accelerating Drug Discovery
CANCER GENETICS INCORPORATED De-risking and Accelerating Drug Discovery ~ we SS ass
Slide 2: Disclaimer
THE FINE PR DISCLAIMER Additional Information about the Proposed Merger and Where to Find It In connection with the proposed Merger between Cancer Genetics ("CGIX") and Stemonix (the "Merger”), CGIX and Stemonix intend to file relevant materials with the Securities and Exchange Commission, or the SE
Slide 3: CGIX Recent History
CGIX RECENT HISTORY THE FUTURE OF DRUG DISCOVERY ented Focused on Precision and Translational Medicine to drive drug discovery and novel therapy development * 2019 Focus on Discovery Initiate M&A strategy to identify strategic Feb 2018 options Focus on core businesses and execute ona transformation
Slide 4: Established and Trusted
ESTABLISHED AND TRUSTED REDEFINING OUR APPROACH The trusted brand for delivering products and services that drive efficient and effective drug development and discovery. Viele CAPITAL MARKET ACCESS Publicly Traded Nasdaq Capital Market Large retail base of shareholders Stemoni» (Cc Fae ye, a) MU WY
Slide 5: Strategy
STRATEGY vivoPharm + Late Stage Cancer Genetics NASDAQ Listed (CGIX) + Proven Leadership + Cancer Big Data + Tumor Line Library + Global Preclinical Experts \ - in vivo Research + Efficacy & Toxicology Stemonix G CANCER GENETICS. INCORPORATED Partners Discovery Engine Speed StemoniX (Discovery) + Da
Slide 6: The CGIX Drug Discovery Engine
THE CGIX DRUG DISCOVERY ENGINE Enhanced 3D human cell Build on Combined Assets and animal models organoids Partnerships - Invert Traditional Drug Discovery x + De-risk toxicity and efficacy through human relevant in vitro screening and in silico Scientific investigation insight * Optimize synergies
Slide 7: Global Footprint
Global Footprint Minneapolis, MN Organoid Production New Jersey HQ ‘Hershey, PA San Diego, CA In vivo Testing Drug Discovery StemoniX | CSN Es eo vn Munich, Germany Qproject Management, Marketing South Australia Toxicology Victoria Safety & Analytical
Slide 8: Led by Passion: Our Team
LED BY PASSION OUR TEAM Post merger with Stemonix Jay Roberts, MBA Ping Yeh, MBA Robert Petcavich, PhD Andy LaFrence, CPA Ralf Brandt, PhD Barb Jones, PhD CEO clo SVP * CFO President Cofounder/CSO of Stemonix KPMG Audit Partner & IPO Readiness Practice 20+ years international standards, regulatory,
Slide 9: Focus on Innovation
FOCUS ON INNNOVATION
Slide 10: Novel Human Biological Models
Novel Human Biological Models Global Leader in Industrialized Human Organoids ¢ High Functionality ¢ High Consistency ¢ High Biological Accuracy Disease Models ¢ Brain: Neurodevelopment, Neurodegeneration ¢ Cardiac: Fibrosis ¢ Pancreas: Diabetes * Oncology Models (brain, pancreas) ix GENETIC | VIVOP
Slide 11: Platforms: Industrialization
BEL PRIZE Y PLATFORMS Industrialization Induced Pluripotent Stem Cell (iPSC) Creation I o> ac cfs, _= W i ” Pancreas Biopsy _Reprogramming iPSCs A E (skin/Blood) Step >» > NOSE Functional Accuracy Differentiation Drtving Csllutar Consistent & Ren EEY High-throughput StemoniX | TSH BBE eo! vue)
Slide 12: Case Study: Brain Cancer
Case Study: Brain Cancer Al Drug Discovery Novel Biological Model + Medidaaltchenuctey Brain Cancer Model Human Brain Organoid + Glioblastoma iT ey Compound Screening in Brain Organoid Silico & Drug Synthesis Tumor Cells Stemonix CGN Beccles Drug Screening & _ Accelerated in vivo Validation 384 Brai
Slide 13: Novel and Repurposed Therapeutics
NOVEL AND REPURPOSED THERABREU TICS
Slide 14: Disease Model Development
DISEASE MODEL DEVELOPMENT Platform Assay Phenotypical Development Development Screening Lead Disease Model Optimization Target ID Rett Syndrome CDKLS Deficiency Disorder Neuro-Spheroid i Platform Midbrain/DOPA [> (Parkinson's) microBrain® Cortical (TBI/Alzheimer's) > Cancer (GBM/ Breast Mets) Cardio
Slide 15: Therapeutic Pipeline
THERAPEUTIC PIPELINE Current State Indications Rett Syndrome Model Screening 1 Lead ID Candidate IND Filing Repurposed Drug Validation Target 1D" Selection : Neurological delays, loss of general = e Rett Syndrome coordination Vion see HitID Leadip Candidate IND Filing Novel Drug i 1 Model Screening
Slide 16: Revenue and Valuation: Commercial Opportunities
REVENUE AND VALUATION COMMERCIAL OPPORTUNITIES
Slide 17: Business Model
BUSINESS MODEL Single Partner Lifetime Value License Out | + Clinical assets / models Contract Work + Screen wi shared economics. Validate: Leverages IP $ Manufacture * Internal Drug c E oki Co-Create: Disease Discovery >) g stablish: Develo Multiple clinical FA Human Organ Ever Model Pp! td Platte
Slide 18: StemoniX and vivoPharm Partner with Global Pharmaceutical Companies
StemoniX and vivoPharm Partner with Global Pharmaceutical Companies + Pharma provides technology validation and supports innovative custom programs P : + Half of the top 25 biopharma companies in the world The International Consortium for are partners Innovation and Quality in Pharmaceutical Develop
Slide 19: Two Business Units
TWO BUSINESS UNITS Discovery Services Well-established R&D to drive the toxicology, efficacy, Where Science i ification of, analytical chemi and equity programs combined Meets interests in, novel with physiologically and redeployed relevant cell-based Technology therapeutics assay (PRCA) platforms
Slide 20: Discovery Services by the Numbers
BY THE DISCOVERY NUMBERS Highly-scalable platform for early discovery, pre IN ACTION ical and pharmacology provides consulting, guidance and preparation of samples and cli ial design in vitroand in vivotesting for Investigational New Drug (“IND”) applications STATE-OF- THE-ART LABS |. CNS, CARDIAC A
Slide 21: Transformational
TRANSFORMATIONAL Building a cutting-edge, technology focused, drug discovery engine to derisk candidate selection through: Stabilizing our Balance Sheet Merging with StemonixX to enhance the value of our existing preclinical business Redesigning fundamental drug discovery to focus on a human-first a
Slide 22: Fall 2020
Nasdaq : CGIX Fall 2020 CANCER GENETICS INCORPORATED [email protected] www.cancergenetics.com
Cancer Genetics — Merger or Acquisition (September 2020) on 6ix